Coronavirus company news summary – Saliva-based antibody test highly accurate in initial study – First SARS-CoV-2 antigen test to be available in Mexico

16 November 2020 (Last Updated November 16th, 2020 09:10)

Chembio Diagnostics has received Agência Nacional de Vigilância Sanitária (ANVISA) regulatory approval to commercialise its DPP SARS-CoV-2 antigen test in Brazil. The test is designed to detect SARS-CoV-2 antigens in just 20 minutes.

The Johns Hopkins Bloomberg School of Public Health has developed a new saliva-based test that can accurately detect antibodies against the SARS-CoV-2 virus. The test is conducted with the help of small saliva samples instead of finger prick blood withdrawals, the results of which can be obtained in hours.

Kabla Diagnosticos has announced the launch of a rapid diagnostic test to detect the SARS-CoV-2 virus antigen in Mexico. The Sofia SARS Ag test was the first to obtain US Food and Drug Administration (FDA) Emergency Use Authorisation (EUA) in the US and is also the first test to be validated by Mexico's Institute of Epidemiological Diagnosis and Reference (INDRE).

Relay Medical and Fio, together known as the Fio Rapid Response Group (FRR), have netted over $500,000 CAD in initial contracts for the Fionet mobile testing and tracking platform. The platform enables widespread testing against infectious diseases, including Covid-19. FRR has collaborated with South Korea’s IVD Lab Co, with funding received from the National Research Council Canada (NRC), to market the new rapid diagnostic test platform. It is currently being validated at Toronto’s University Health Network (UHN).